Verrica Taps Dermavant Exec as CCO to Drive YCANTH Expansion
Event summary
- Verrica appointed Chris Chapman as Chief Commercial Officer on February 12, 2026.
- Chapman previously led commercial efforts at Dermavant Sciences and Galderma.
- YCANTH, Verrica's FDA-approved treatment for molluscum contagiosum, covers 250M insured lives.
- Verrica is developing YCANTH for common warts and VP-315 for basal cell carcinoma.
The big picture
Verrica's appointment of Chapman underscores its push to establish YCANTH as the standard of care for molluscum, a market with significant unmet need. The move comes as dermatology therapeutics face increasing competition, particularly in indications like psoriasis and atopic dermatitis where new treatments are emerging. Chapman's background in commercializing dermatology products positions Verrica to capitalize on YCANTH's growth potential while navigating a dynamic regulatory and competitive landscape.
What we're watching
- Commercial Execution
- How Chapman's experience will accelerate YCANTH adoption in molluscum and expand into common warts.
- Pipeline Progress
- The pace at which Verrica advances VP-315 through global Phase 3 trials for basal cell carcinoma.
- Market Penetration
- Whether Verrica can sustain momentum in a competitive dermatology market with limited FDA-approved therapies.
Related topics